Although current guidelines do not set specifi c targets for lowering levels of low-density lipoprotein cholesterol (LDL-C), several lines of evidence support the concept that "lower is better." Statin drugs in combination with new agents now make it possible to lower LDL-C to new lows. Determining the risk of cardiovascular disease in apparently healthy adults and how far to extend treatment for primary prevention has critical implications for public health.
T
he 2013 joint guidelines of the American College of Cardiology and American Heart Association (ACC/AHA) 1 on the treatment of blood cholesterol to reduce cardiovascular risk recommend high-intensity statin therapy for secondary prevention of cardiovascular events. The question of primary prevention is not so straightforward, and the recommended strategy has come under fi re. In addition, the guidelines focus on statins and not on LDL-C levels, and the role of nonstatin lipid-lowering drugs and the value of reducing LDL-C levels to well below levels currently regarded as "normal" remain unclear.
This article comments on the 2013 ACC/ AHA guidelines, reviews the data on optimal LDL-C levels, and discusses new nonstatin agents.
■ ACC/AHA GUIDELINES: A MIXED MESSAGE
The 2013 ACC/AHA cholesterol guidelines 1 can be characterized by the title from the famous Western fi lm "The Good, the Bad, and the Ugly."
The good: A clear message to treat
The guidelines deliver an unambiguous message to treat patients at high risk with highintensity statin therapy. This mandate is very helpful as it should reduce the undertreatment of patients.
The seemingly bad
Two common misconceptions regarding the guidelines: They abandon LDL-C targets. Actually, the guidelines do not argue for or against targets; they simply remain silent, citing that randomized trials have not been conducted with LDL-C targets as specifi c goals. Technically, this statement is true. However, it seems contrived to argue, for example, that the benefi t 
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SABATINE
of atorvastatin 80 mg over 10 mg in the Treating to New Targets trial could not be reliably ascribed to the lower LDL-C achieved with the higher dose, but rather to some undefi ned benefi t of high-intensity statin therapy, especially as the guidelines defi ne the intensity of statins by the degree of LDL-C lowering. In fact, by correlating the incidence of coronary heart disease events with the levels of LDL-C achieved in those trials, conclusions can reasonably be drawn from such data (Figure 1 ).
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The guidelines do not recommend nonstatin drugs. Actually, the guidelines note that clinicians are free to consider other therapies, especially those proven to reduce the risk of cardiovascular events, a central principle of medicine. Since the guidelines were published, data have emerged indicating that the role of nonstatin drugs also needs consideration.
The ugly: Risk calculator untested
The guidelines promote the use of a risk calculator developed by the ACC/AHA to estimate the 10-year risk of an atherosclerotic event for people whose LDL-C levels are between 70 and 189 mg/dL to help decide whether to initiate statin therapy for primary prevention of atherosclerotic cardiovascular disease. Such an approach is reasonable, although the risk score was promulgated without evidence to support its utility.
Media coverage of the risk calculator was fi erce. Some physicians found imperfections in the risk score (as is true for all risk scores), resulting in public mistrust of the guidelines and of the medical community as a whole. This needless controversy may have compromised the main message-that LDL-C should be lowered in many people-a message backed by strong evidence.
Alternative strategies proposed
Ridker et al 3 have proposed a hybrid strategy to guide statin use for apparently healthy people that combines the ACC/AHA guideline approach with entry criteria for randomized clinical trials that showed statin effi cacy for primary prevention.
Genetic analysis may offer another approach. Mega et al 4 stratifi ed more than 48,000 people by a genetic risk score based on 27 genetic variants and found a signifi cant association with risk of coronary events. Targeting therapy to people found to be at higher risk on this basis offers greater risk reduction than expected for the general population. Biomarkers and imaging tests are other potentially useful risk determinants.
■ LDL-C: LOWER IS BETTER
Although no clinical trial has yet targeted specifi c LDL-C levels, there is plenty of evidence that lower LDL-C levels offer greater benefi t (Figure 1) . 2 In 1994, the Scandinavian Simvastatin Survival Study 5 established the benefi t of statins in patients with known vascular disease. The mean LDL-C level achieved in the active treatment group was 120 mg/dL. More trials followed supporting the benefi ts of statins and of reducing LDL-C from average levels in the 120s down to 100 mg/dL.
In 2004, the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial 6 observed an even greater risk reduction in patients with known risk by treating with statins; the mean LDL-C level achieved in the group randomized to an intensive regimen of atorvastatin 80 mg per day was 62 mg/dL. The same year, the Adult Treatment Panel III of the National Cholesterol Education Program 7 issued updated guidelines including an optional goal of LDL-C less than 70 mg/dL for patients at very high risk.
In 2008, the Justifi cation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) 8 found a signifi cantly lower incidence of major cardiovascular events at 2 years in apparently healthy men and women with baseline LDL-C levels of less than 130 mg/dL after treatment with rosuvastatin 20 mg daily, with an achieved median LDL-C of 55 mg/dL.
How low should LDL-C go?
Evidence from clinical trials indicates a 20% to 25% reduction in the risk of cardiovascular events for every 39-mg/dL decrease in LDL-C. Extrapolating the data, cardiovascular disease risk would be reduced to zero if LDL-C were brought down below 40 mg/dL.
Brown and Goldstein, 9 who won the 1985 Nobel Prize in medicine for their work in choTreat high-risk patients with high-intensity statins lesterol metabolism, estimated that a plasma level of LDL-C of only 25 mg/dL would be suffi cient to nourish cells with cholesterol. Cells can synthesize all the cholesterol they need, underscoring that LDL-C is simply the fi nal end-product that the liver removes from circulation.
Other evidence that lower LDL-C does not have adverse effects comes from non-Western populations as well as from other mammals. Total cholesterol levels range in the low 100s mg/dL in Native American and African tribal populations, with LDL-C estimated to be about 50 to 75 mg/dL. Elephants, baboons, and foxes have even lower levels. 10 Clinical trial data also support that LDL-C levels below the current "normal" are better. The Cholesterol Treatment Trialists' Collaboration 11 analyzed data from more than 160,000 patients in 26 trials that evaluated either more-vs less-intensive statin regimens or statin treatment vs control. No baseline level below which lowering LDL-C further was not benefi cial was found. Patients who started out with an LDL-C level of less than 77 mg/dL had the same risk reduction of major vascular events when the level was dropped to 50 mg/ dL as those who started at higher levels and reduced their LDL-C by the same amount. In the JUPITER trial, even those with a baseline LDL-C of less than 60 mg/dL benefi ted from statin therapy. 12 
■ BEYOND STATINS Ezetimibe further lowers risk
Ezetimibe is a nonstatin drug that reduces LDL-C by about 15% to 20%. The Improved Reduction of Outcomes: Vytorin Effi cacy International Trial 13 registered more than 18,000 patients with a baseline LDL-C level of less than 125 mg/dL (or 100 mg/dL if already on lipid-lowering therapy) who had been stabilized shortly after an acute cardiovascular event. They were randomized to receive either simvastatin 40 mg or combined simvastatin 40 mg and ezetimibe 10 mg. The study intended to determine two things: whether ezetimibe could further lower LDL-C when combined with a statin, and whether risk could be reduced further by driving the LDL-C below 70 mg/dL and down to the mid-50s. After 1 year, the average LDL-C level was 70 mg/dL in the simvastatin group and 53 mg/ dL in the combined simvastatin and ezetimibe group. At 7 years, for the primary end point (cardiovascular death, myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, or stroke), there was a 6% reduction of events in the combined drug treatment group, with the number of people needed to treat being 50 to prevent one event.
For the narrower end point of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, there was a 10% risk reduction in the combined drug treatment arm. 14 The amount of risk reduction is exactly what was predicted by the Cholesterol Treatment Trialists' Collaboration's plot of reduction in events vs reduction in LDL-C based on the analysis of 26 trials, adding further evidence that it is the LDL-C reduction itself, rather than the means by which LDL-C is reduced, that is critical for benefi t.
PCSK9 inhibitors: A new approach
Mutations in the gene for proprotein convertase subtilisin kexin type 9 (PCSK9) have become a new focus of interest for reducing LDL-C and cardiovascular risk.
15 PCSK9 binds to the LDL-C receptor on the surface of hepatocytes and escorts it to its destruction in the lysosomes, rather than allowing it to return to the cell surface to take more LDL-C out of circulation.
People with a gain-of-function mutation (conferring too much PCSK9, resulting in fewer LDL-C receptors and more LDL-C in circulation) are a more recently recognized subset of those with autosomal-dominant familial hypercholesterolemia. They have total cholesterol levels in the 90th percentile, tendon xanthomas, and a high risk of myocardial infarction and stroke at a young age.
Conversely, those with a nonsense mutation in PCSK9-leading to loss of functionhave a 28% reduction in mean LDL-C and 88% reduction in risk of coronary heart disease compared with those without the mutation. 16 Two women (ages 32 and 21, fertile) have been found who have inactivating mutations in both PCSK9 alleles, and both are in apparent good health, with LDL-C levels of 14 mg/dL and 15 mg/dL, respectively.
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Mounting evidence indicates that 'normal' LDL-C levels may be too high SABATINE Dramatic reduction in LDL-C Monoclonal antibodies have been developed that bind PCSK9 and block its action with the goal of developing new LDL-C-lowering treatments. Phase 2 clinical trials of varying doses of evolocumab (Repatha), a drug in this class, combined with standard therapy (a statin with or without ezetimibe), found a 66% reduction of LDL-C at high doses at 12 weeks compared with standard therapy alone, with concomitant reductions in other atherogenic lipoproteins. 19 Patients who could not tolerate statins because of myalgia responded well to evolocumab. 20 Patients with heterozygous familial hypercholesterolemia also had a substantial reduction in LDL-C (55% at the highest dosage), even though they have fewer LDL-C receptors for the drug to act upon. 21 People with homozygous familial hypercholesterolemia and no LDL-C receptors had a lesser relative reduction in LDL-C that depended on the type of mutations they had. Nonetheless, given how high LDL-C levels are in this population, the absolute decreases in LDL-C level were quite impressive.
Cardiovascular risk reduced
Data at nearly 1 year showed continued reduction of LDL-C by about 60% (absolute reduction: 73 mg/dL), as well as a lower incidence of cardiovascular events starting at just 3 months, much sooner than observed in some statin trials. 22 Benefi ts were found regardless of subgroup (sex, age, statin use, baseline LDL-C level, or known vascular disease). No difference was found in the safety profi le between the evolocumab and control arms. Only 2.4% of participants discontinued evolocumab because of adverse events, and the incidence of adverse effects did not correlate with LDL-C level achieved. Neurocognitive effects occurred in 0.9% of the evolocumab arm vs 0.3% in the control arm. This difference has not been explained: although there is cholesterol in the central nervous system, it is generated locally, and lipoproteins-and evolocumab-are not thought to cross the blood-brain barrier.
Long-term trials of evolocumab are currently under way for patients with cardiovascular disease, as are trials of two other PCSK9 inhibitors, alirocumab and bococizumab, in addition to standard statin therapy.
On July 24, 2015, the US Food and Drug Administration (FDA) approved the fi rst PCSK9 inhibitor, alirocumab (Praluent) for patients with heterozygous familial hypercholesterolemia or those with clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The starting dosage is 75 mg subcutaneously every 2 weeks, which can be increased up to 150 mg every 2 weeks.
Evolocumab was approved by the FDA on August 27, 2015, for the same indications. The dosage is 140 mg subcutaneously every 2 weeks or 420 mg every month. 
